[go: up one dir, main page]

CR20190087A - Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica - Google Patents

Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica

Info

Publication number
CR20190087A
CR20190087A CR20190087A CR20190087A CR20190087A CR 20190087 A CR20190087 A CR 20190087A CR 20190087 A CR20190087 A CR 20190087A CR 20190087 A CR20190087 A CR 20190087A CR 20190087 A CR20190087 A CR 20190087A
Authority
CR
Costa Rica
Prior art keywords
prophylaxis
treatment
virus infection
compounds
substituted
Prior art date
Application number
CR20190087A
Other languages
English (en)
Inventor
Chungen Liang
Lu Gao
Kun Miao
Bo Zhang
Xiufang Zheng
Jianping Wang
Hongying Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20190087A publication Critical patent/CR20190087A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) en la que R1, R2 y R3 son tal como se indica en la presente memoria y sus profármacos o sal, enantiómero o diastereómero farmacéuticamente aceptable del mismo, y composiciones que incluyen los compuestos y métodos de utilización de los compuestos
CR20190087A 2016-08-29 2017-08-28 Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica CR20190087A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12
PCT/EP2017/071514 WO2018041763A1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
CR20190087A true CR20190087A (es) 2019-04-30

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190087A CR20190087A (es) 2016-08-29 2017-08-28 Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica

Country Status (29)

Country Link
US (3) US10233184B2 (es)
EP (2) EP3504210B1 (es)
JP (2) JP7013467B2 (es)
KR (2) KR102459155B1 (es)
CN (1) CN109641904B (es)
AU (3) AU2017320742B2 (es)
CA (1) CA3034148A1 (es)
CL (1) CL2019000512A1 (es)
CO (1) CO2019000932A2 (es)
CR (1) CR20190087A (es)
DK (1) DK3504210T3 (es)
ES (1) ES2867849T3 (es)
HR (1) HRP20210621T1 (es)
HU (1) HUE053944T2 (es)
IL (3) IL293475B2 (es)
MA (1) MA46038B1 (es)
MX (2) MX383500B (es)
MY (1) MY197408A (es)
PE (1) PE20190476A1 (es)
PH (1) PH12019500432B1 (es)
PL (1) PL3504210T3 (es)
PT (1) PT3504210T (es)
RS (1) RS61752B1 (es)
RU (1) RU2751349C2 (es)
SG (2) SG10202010520SA (es)
SI (1) SI3504210T1 (es)
TW (1) TWI671300B (es)
UA (1) UA124270C2 (es)
WO (1) WO2018041763A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102690131B1 (ko) * 2015-05-08 2024-07-31 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체
PT3504210T (pt) * 2016-08-29 2021-04-19 H Hoffnabb La Roche Ag Compostos de sulfonimidoílpurinona 7-substituídos para o tratamento e profilaxia de infeção por vírus
CN109715214B (zh) * 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
CN111801100B (zh) * 2018-02-28 2023-10-24 豪夫迈·罗氏有限公司 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023516372A (ja) 2020-03-02 2023-04-19 プロジェニア インコーポレイテッド 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031057A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
CN114315861A (zh) * 2020-09-27 2022-04-12 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
GB202306325D0 (en) 2023-04-28 2023-06-14 Iksuda Therapeutics Ltd Antibody-drug conjugate compounds, and methods of use and treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US6329381B1 (en) * 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EP1490015B1 (en) 2002-03-15 2009-09-23 Wayne State University Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents
AU2003271064B2 (en) * 2002-09-27 2010-06-17 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound and use thereof
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
EA021463B1 (ru) * 2007-06-29 2015-06-30 Джилид Сайэнс, Инк. Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
TW201639852A (zh) * 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
WO2011049825A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
SI3190113T1 (sl) 2014-08-15 2021-09-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pirolopirimidinske spojine, ki se uporabljajo kot agonist TLR7
KR102690131B1 (ko) * 2015-05-08 2024-07-31 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체
PT3504210T (pt) * 2016-08-29 2021-04-19 H Hoffnabb La Roche Ag Compostos de sulfonimidoílpurinona 7-substituídos para o tratamento e profilaxia de infeção por vírus

Also Published As

Publication number Publication date
IL284255A (en) 2021-07-29
RU2019107957A (ru) 2020-09-29
MX2019002129A (es) 2019-06-20
SG10202010520SA (en) 2020-11-27
JP7013467B2 (ja) 2022-01-31
US10233184B2 (en) 2019-03-19
SI3504210T1 (sl) 2021-08-31
MX383500B (es) 2025-03-14
AU2022204697A1 (en) 2022-07-21
CN109641904A (zh) 2019-04-16
DK3504210T3 (da) 2021-04-26
PH12019500432A1 (en) 2019-10-21
JP2022050632A (ja) 2022-03-30
RS61752B1 (sr) 2021-05-31
EP3504210B1 (en) 2021-02-24
MX2021006902A (es) 2021-07-07
KR20190039829A (ko) 2019-04-15
TW201819382A (zh) 2018-06-01
IL293475B2 (en) 2024-10-01
US10752630B2 (en) 2020-08-25
IL293475B1 (en) 2024-06-01
RU2019107957A3 (es) 2020-12-18
JP7214900B2 (ja) 2023-01-30
KR20220147702A (ko) 2022-11-03
CL2019000512A1 (es) 2019-07-12
AU2017320742A1 (en) 2019-02-28
AU2017320742B2 (en) 2021-08-05
US20180072730A1 (en) 2018-03-15
KR102459155B1 (ko) 2022-10-28
MY197408A (en) 2023-06-16
PE20190476A1 (es) 2019-04-04
UA124270C2 (uk) 2021-08-18
EP3865482A1 (en) 2021-08-18
SG11201901633WA (en) 2019-03-28
MA46038B1 (fr) 2021-05-31
IL293475A (en) 2022-08-01
US20200385387A1 (en) 2020-12-10
AU2021204303B2 (en) 2022-05-12
MA46038A (fr) 2019-07-03
PL3504210T3 (pl) 2021-07-05
HUE053944T2 (hu) 2021-08-30
WO2018041763A1 (en) 2018-03-08
TWI671300B (zh) 2019-09-11
CO2019000932A2 (es) 2019-02-08
US20190256515A1 (en) 2019-08-22
CA3034148A1 (en) 2018-03-08
JP2019526633A (ja) 2019-09-19
IL264710B (en) 2021-07-29
HRP20210621T1 (hr) 2021-05-28
PT3504210T (pt) 2021-04-19
ES2867849T3 (es) 2021-10-21
RU2751349C2 (ru) 2021-07-13
AU2021204303A1 (en) 2021-07-22
NZ750604A (en) 2024-02-23
CN109641904B (zh) 2022-01-28
BR112019003519A2 (pt) 2019-05-21
IL284255B (en) 2022-07-01
EP3504210A1 (en) 2019-07-03
PH12019500432B1 (en) 2023-03-24

Similar Documents

Publication Publication Date Title
CR20190087A (es) Nuevos compuestos sulfonimidoilpurinova 7-sustituídos y derivados para el tratamiento y la profilaxis de la infección vírica
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
ECSP16016726A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
SV2017005381A (es) Compuestos de imidazopiridazina
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CR20170462A (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda
NI201600163A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
ECSP14011505A (es) Derivados de bencil sulfonamida útiles como inhibidores de mogat-2